Recent Updates
Recently added Catalysts
ATYR Positive Sentiment

A Human Histidyl-tRNA Synthetase Splice Variant Therapeutic Targets NRP2 to Resolve Lung Inflammation and Fibrosis

Monday, April 21, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses a therapeutic approach involving a human histidyl-tRNA synthetase splice variant that targets NRP2. This innovative treatment aims to alleviate lung inflammation and fibrosis, which are critical conditions affecting respiratory health. The findings are set to be published in Science Translational Medicine in 2025, highlighting the potential impact of this research.
Price reaction · baseline $3.1 (2025-04-17 close) · hit pre-market · clean, no other ATYR news in the window
day 0 close
+5.8%
day 1 · peak
+11.9%
day 3
+11.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • The therapeutic targets NRP2, which may effectively resolve lung inflammation.
  • Potential to address lung fibrosis, a significant health issue.
  • Research published in a reputable journal, indicating scientific validation.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+41%
120-day peak, hindsight
Typical move
5.7%
average across 7 past catalysts
Cash runway
~18 mo
Low dilution risk
Lead asset
Efzofitimod/kg
Phase 3 · Pulmonary Sarcoidosis

Full Press Release Details

Nangle LA, Xu Z, Siefker D, Burkart C, Chong YE, Zhai L, Geng Y, Polizzi C, Guy L, Eide L, Tong Y, Klopp-Savino S, Ferrer M, Rauch K, Wang A, Hamel K, Crampton S, Paz S, Chiang K, Do M, Burman L, Lee D, Zhang M, Ogilvie K, King D, Adams RA, Schimmel P. Science Translational Medicine (2025)

Frequently Asked Questions

What is the focus of the research article?

The research focuses on a therapeutic targeting NRP2 to resolve lung inflammation and fibrosis.

Where will the findings be published?

The findings are set to be published in Science Translational Medicine in 2025.

What health issues does the therapy aim to address?

The therapy aims to address lung inflammation and fibrosis, significant respiratory health issues.

ShareAdd on Google
Tags: ATYR Viatris Investor Conferences Healthcare lung inflammation fibrosis NRP2 therapeutic
Last updated: Apr 21, 2025

Biotech snapshot

Cash runway
$57M liquidity · $3M/mo burn
~18 mo
Low dilution risk
Lead asset
Efzofitimod/kgPhase 3
Pulmonary Sarcoidosis →

Catalyst track record

+41%
best trade around ATYR's most recent catalyst

Peak hindsight return over a 120-day window, across 7 tracked FDA/PDUFA catalysts for ATYR.

See every catalyst's timing & PoA →